A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Trial Profile

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Plinabulin (Primary) ; Pegfilgrastim
  • Indications Neutropenia
  • Focus Registrational; Therapeutic Use
  • Acronyms Protective-1
  • Sponsors BeyondSpring Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2017 According to a BeyondSpring Pharmaceuticals media release, the company expects reporting Phase 2 efficacy data in the second half of 2017 and Phase 3 interim data in 2018, as well as in submitting a New Drug Application (NDA) in 2019 to the FDA and CFDA.
    • 06 Jul 2017 According to a BeyondSpring Pharmaceuticals media release, the China Food and Drug Administration (CFDA) has approved the Company's Clinical Trial Applications (CTAs) to allow the initiation of the phase II/III trial of Plinabulin.
    • 15 Jun 2017 According to BeyondSpring Pharmaceuticals media release, the company will present data from this study at the 2017 BIO International Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top